Boehringer Ingelheim's new 120 million euro Investment in Greece
- Written by E.Tsiliopoulos
The research-driven biopharmaceutical company Boehringer Ingelheim announced that it will invest 120 million euros to expand and upgrade its plant in Greece.
In a press release on Thursday, the company explained that the Greece-based investment is slotted for its existing plant in Koropi, which is located in the Attica region.
The funds will enable the plant to increase the manufacturing capacity of the plant in regards to new and existing medications and will add 110 new jobs.
Some of the key disease areas addressed by the medications produced by the plant include cardio-renal-metabolic (CRM) diseases, mental health and pulmonary fibrosis.
Exports of a well-known drug for type 2 diabetes, heart failure and chronic kidney disease called Jardiance will be enhanced and sent to the USA.
The ceremony where the announcement was made was attended by Greek Prime Minister Kyriakos Mitsotakis, Greek Minster of State, the Minister of Health and the Minister of Development.
Related items
- Greek Beach Visitors Can Report Violations on New ‘MyCoast’ App
- Education Min Pierrakakis raises Chora Monastery conversion issue during Vatican visit
- Greece establishes experimental school for specialized training in tourism
- Appellate public prosecutor lodges appeal against judgement for Mati fire
- Olympic Flame to arrive at the port of Marseille on Wednesday
Latest from E.Tsiliopoulos
- Greek Beach Visitors Can Report Violations on New ‘MyCoast’ App
- Education Min Pierrakakis raises Chora Monastery conversion issue during Vatican visit
- Greece establishes experimental school for specialized training in tourism
- Appellate public prosecutor lodges appeal against judgement for Mati fire
- Olympic Flame to arrive at the port of Marseille on Wednesday